Analysis of Mortality of Critically Ill Patients With COVID-19

NCT04379258 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 868

Last updated 2021-09-28

No results posted yet for this study

Summary

The recent pandemic of the COVID-19 disease has caused a national health emergency due to its severity and the clinical and social consequences of the disease. Crude mortality in Spain is 9.2%. However, the causes of death of critically ill patients with COVID-19 are unknown. To date, no treatment has been shown to be effective for the 2019-SARS-CoV-2 infection is recommended. Supportive care and isolation are recommended for infected individuals. Currently, observational studies on critically ill patients with COVID-19 have small samples. The objective is to evaluate the incidence of mortality and morbidity in COVID-19 disease in this group of critically ill patients, as well as the risk factors associated with mortality and the effectiveness of the treatments used compassionately.

Conditions

  • COVID-19
  • Critical Illness
  • Effectiveness
  • Outcome, Fatal

Sponsors & Collaborators

  • Hospital Universitario del Tajo

    collaborator UNKNOWN
  • Puerta de Hierro University Hospital

    collaborator OTHER
  • Hospital de Henares

    collaborator OTHER
  • Hospital Universitario Ramon y Cajal

    collaborator OTHER
  • Hospital Universitario de Móstoles

    collaborator OTHER
  • Hospital Universitario Severo Ochoa

    collaborator UNKNOWN
  • Fundación de Investigación Biomédica - Hospital Universitario de La Princesa

    collaborator OTHER
  • Hospital Universitario Madrid Sanchinarro

    collaborator OTHER
  • Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

    collaborator OTHER
  • Hospital Universitario Infanta Cristina

    collaborator OTHER
  • Hospital General Universitario Gregorio Marañon

    collaborator OTHER
  • Hospital Universitario de Torrejón

    collaborator UNKNOWN
  • Hospital Universitario La Paz

    collaborator OTHER
  • Hospital Universitario 12 de Octubre

    collaborator OTHER
  • Hospital Christus Muguerza Betania, Puebla, Mexico

    collaborator UNKNOWN
  • Hospital General de Mexico

    collaborator OTHER_GOV
  • Hospital Regional 1º de Octubre ISSSTE Mexico

    collaborator UNKNOWN
  • Hospital Juarez de Mexico

    collaborator OTHER_GOV
  • Hospital Gea Gonzalez Mexico

    collaborator UNKNOWN
  • Hospital Civil de Guadalajara

    collaborator OTHER
  • Hospital Regional de alta Especialidad Ixta, Mexico

    collaborator UNKNOWN
  • Hospital Ángeles Tampico, Mexico

    collaborator UNKNOWN
  • Hospital de la Beneficiencia Espaañola, Tampico, Mexico

    collaborator UNKNOWN
  • Hospital Ángeles Tijuana, Mexico

    collaborator UNKNOWN
  • Hospital Universitario UANL, Mexico

    collaborator UNKNOWN
  • Hospital H+ Querétaro, Mexico

    collaborator UNKNOWN
  • Hospital General de Zona 1A Venados, Mexico

    collaborator UNKNOWN
  • Centro Médico ABC Observatorio, Mexico

    collaborator UNKNOWN
  • Hospital Christus Muguerza Alta Especialidad, Nuevo León, Mexico

    collaborator UNKNOWN
  • Hospital Universitario Getafe

    lead OTHER

Principal Investigators

  • Oscar Peñuelas, P.h.D · Fundación de Investigación del Hospital Universitario de Getafe

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-08
Primary Completion
2021-02-08
Completion
2021-02-08

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04379258 on ClinicalTrials.gov